

# Formulation & evaluation of Voriconazole nanoparticles for ophthalmic drug delivery system

Anukalp Pandey\*, Rishab Shukla and Seema Sahu

RKDF College of Pharmacy, Bhopal. Behind Hotel Mark, Hoshangabad Road (Narmadapuram Road), Jatkhedi, Misrod, Bhopal SRK University, Bhopal, M.P.462-026, India

## \*Correspondence Info:

Mr. Anukalp Pandey,  
RKDF College of Pharmacy,  
Bhopal. Behind Hotel Mark, Hoshangabad Road  
(Narmadapuram Road), Jatkhedi, Misrod, Bhopal SRK  
University, Bhopal, M.P.462-026, India

## \*Article History:

Received: 17/08/2025

Revised: 27/09/2025

Accepted: 28/09/2025

DOI: <https://doi.org/10.7439/ijap.v14i1.5873>

## Abstract

Voriconazole is a second-generation antifungal agent with excellent broad spectrum of antifungal activity commercially available for oral and intravenous administration. Systemic administration of voriconazole is associated with side effects including visual and hepatic abnormalities. This study assessed the feasibility of using solid lipid nanoparticles for ocular delivery of voriconazole adopting stearic acid as lipidic material, tween 80 as a stabilizer, and Carbopol 934 as controlled release agent and for increasing the precorneal residence time in eye. The systems were prepared using two different methods, that is, ultrasonication method and microemulsion technique. The results indicated that the larger particle size of SLNs was found with microemulsion technique ( $308 \pm 3.52 \text{ nm}$  to  $343 \pm 3.51$ ) compared to SLN prepared with ultrasonication method ( $234 \pm 3.52 \text{ nm}$  to  $288 \pm 4.58 \text{ nm}$ ). The polydispersity index values were less than 0.3 for all formulations and zeta potential of the prepared formulations by these two methods varied from  $-22.71 \pm 0.63 \text{ mV}$  to  $-28.86 \pm 0.58 \text{ mV}$ . Powder X-ray diffraction and differential scanning calorimetry indicated decrease in crystallinity of drug. The *in vitro* release study and the SLN formulations prepared with ultrasonication method demonstrated sustained release up to 12 hours. This study demonstrated that SLN prepared by ultrasonication method is more suitable than microemulsion technique without causing any significant effect on corneal hydration level.

**Keywords:** Voriconazole, nanoparticles, Lyophilization.

## 1. Introduction

Eye is the most simply accessible site for topical administration of a medication. Drugs are commonly applied to the ocular system for a localized action on the surface or in the interior of the eye [1]. The major challenge to the formulator is to outwit these barriers without causing any tissue damage [2]. The cornea is the anterior layer of the eye, comprised of epithelium, stroma, and endothelium. However, this layer represents a mechanical barrier restraining the delivery of drug molecules. Due to their high lipid content, the epithelium and the endothelium are considered as an obstruction to the passage of hydrophilic molecules. The stroma is characterized by a high-water content that makes this layer impermeable to lipophilic molecules [3]. Corneal barrier also plays a considerable role in low ocular bioavailability due to which only <5% of the applied drugs are able to penetrate through the cornea into the intraocular tissues [4]. As a result, to optimize ocular

drug delivery, different strategies were developed to increase the bioavailability of drugs in the front of eye to prolong time. An ideal ophthalmic drug delivery must be able to release the drug in sustained manner and remain in the front of eye to prolong period of the time. As a result, various attempts have been made to prolong the residence time of drug on the ocular surface and also to slow down the drug elimination [5, 6]. To overcome the above problems related to ocular delivery, novel drug delivery systems (NDDS) consisting mainly of nanoemulsions, liposomes, microemulsions, microspheres, and solid lipid nanoparticles (SLNs) have been projected newly for oral, topical, and parental administration of drugs [6, 7]. SLN represented an exceptional carrier system to conventional colloidal carriers, such as emulsions, lipid emulsion, liposomes, and polymeric microparticles, and so forth. SLNs are submicron colloidal carriers ranging from 50 to 1000 nm, which are composed of physiological lipid, dispersed in water or in aqueous surfactant solution [8].

They are appropriate for the incorporation of lipophilic, hydrophilic, and poorly water-soluble drugs [9]. Various researchers have been working in the area of ocular drug delivery; that is, formulated meloxicam solid lipid nanoparticles were formulated and it was concluded that SLNs have excellent physical stability, high entrapment efficiency, and sustained drug release and also represent a promising carrier for topical delivery of meloxicam [10]. Some researchers describe the preparation and characterization of solid lipid nanoparticles (SLNs) prepared with stearic acid (SLN-A) and a mixture of stearic acid and Compritol (SLN-B) as lipid matrix and poloxamer-188 as surfactant, using sodium taurocholate and ethanol as co surfactant mixture, which proves SLN to be a good ocular drug delivery system considering the smaller particle size, particle size stability, physiologically tolerable components, and so forth [9]. Amphotericin B and natamycin fungal ulcers tend to have very poor outcomes. Since 1960 no new medications have been permitted by the FDA and there has been only a randomized trial of antifungal therapy for fungal ulcers [11]. There are studies that indicate the newer triazoles; that is, voriconazole is a novel second generation triazole derivative of fluconazole with exceptional broad-spectrum activity commercially available for oral and intravenous administration. Voriconazole has broad *in vitro* antifungal activity against yeasts and moulds, including a broad range of less common pathogens. Voriconazole possesses fungicidal *in vitro* activity against all *Aspergillus* species, moulds such as *Scedosporium* species and *Fusarium* species, and is highly potent against fluconazole-resistant *Candida* species including *Candida krusei*, *Candida glabrata*, and *Candida albicans*. The minimum inhibitory concentrations (MIC<sub>90</sub>) of voriconazole are considerably less than that of fluconazole. It inhibits cytochrome P450-dependent 14 $\alpha$  sterol demethylase enzyme which is responsible for inhibiting and disrupting fungal cell membrane synthesis, resulting in depletion of ergosterol [12]. Voriconazole marketed formulations are also present; namely, Vozole is a lyophilized powder (VCZ eye drops 1% w/v and VCZ injection 1mg/vial). Voriconazole is a lipophilic drug with a low Ph dependent aqueous solubility (maximum 2.7mg/mL at pH 1.2). To improve the accessibility of voriconazole at the intraocular level, voriconazole loaded solid lipid formulations were prepared. Stearic acid is a saturated, wax-like, fatty acid commonly used in the production of SLNs. In addition to this, it has excellent biodegradability and has low toxicity and also incorporates both hydrophilic and lipophilic drugs [13]. Tween 80 is a nonionic surfactant derived from sorbitan esters and acting as stabilizer in the preparation [14]. Carbopol 934 is a polyacrylic polymer

which has inherent muco-adhesiveness, acts as controlled release agent, and also prolongs the precorneal residence time and avoids systemic side effects [15]. The purpose of the study was to formulate voriconazole loaded-SLN formulations as sustained ocular drug delivery systems with the aim of improving availability of voriconazole at the intraocular level. It was proposed to prepare the SLN of voriconazole by both ultra sonication and micro emulsion techniques so that the best suitable method out of these two can be projected and to determine the effect of formulation factors on the trans corneal permeation of voriconazole through freshly excised goat corneas [16].

## 2. Materials and Methods

Voriconazole was received as gift samples from Matrix Laboratories, Hyderabad (India), and stearic acid and Carbopol 934 were purchased from Sigma-Aldrich Pvt. Ltd. (India). All other chemicals used were of analytical reagent grade. Fresh whole eyeballs of goat were obtained from local butcher's shop (Zirakpur, Punjab, India) within one hour of slaughtering of animal [17].

### 2.1 Ultra sonication Method

Firstly, stearic acid was melted in porcelain dish (for relaxation of lipid side chain) and then required quantity of tween 80 was added. Secondly, drug was soluble in dichloromethane and this drug solution was added in the above lipid phase. The detailed formulae of VCZ loaded SLNs with their percentage (w/w or w/v) are given in Table 1. An aqueous phase containing different concentrations of Carbopol 934 was prepared in 20mL of distilled water with constant stirring and heating at approximately 70°C in which lipid phase is added slowly. The prepared solution was stirred at 2000 rpm for 3min and instantly ultra sonicated by probe sonicator (PCI analytics, Mumbai, India). Ultra sonication was done by adjusting frequency 0.5 for 30min at 45% amplitude. After sonication, the dispersion was diluted with 80ml of distilled cold water under continuous stirring for 15min [18]. A stable SLN suspension of voriconazole by ultrasonication (VUSLN) was obtained.

### Principle

**High-frequency ultrasonic waves** (typically 20–40 kHz) are applied to the solid–liquid mixture.

This causes **acoustic cavitation**—rapid formation, growth, and collapse of microscopic bubbles in the liquids. The collapse of bubbles releases intense microjets, shock waves and shear forces.

These forces break down agglomerates of solid particles and reduce them to the nanoscale while dispersing them uniformly in the liquid medium.

**Table 1: Tyes of Ultrasonication For Solid-Liquid Nanoparticles**

Method	Equipment	Purpose
<b>Probe Sonication</b>	Ultrasonic probe (horn tip) directly immersed in the suspension	High –energy efficient for reducing particle size and breaking aggregates
<b>Bath sonication</b>	ultrasonic bath where the container is placed in water bath	Lower energy, mainly for dispersion and cleaning rather than major size reduction
<b>Tip/Probe Sonication with Pulsed Mode</b>	Alternating On-Off pulses	Prevents overheating maintains stability of nanoparticles
<b>Dual-frequency Sonication</b>	Combination of different frequencies	Improves dispersion and size uniformity

**2.2 Micro emulsion Technique**

In this technique, stearic acid was melted in porcelain dish (for relaxation of lipid side chain) and then required quantity of tween 80 was added [19].Then, drug was soluble in dichloromethane and this drug solution was added in the above lipid phase. The detailed formulae of VCZ loaded SLNs with their percentage (w/w or w/v) are given in Table 1.

An aqueous phase containing different concentrations of Carbopol 934 was prepared in 20mL of distilled water in which lipid phase is added slowly with constant stirring and heating at approximately 70°C for 15 minutes. The solid lipid nanoparticles were obtained by dispersing warm o/w micro emulsion drop wise into cold water (2-3°C) in a beaker under continuous stirring at 2000 rpm for 4 hr. After completion of stirring, SLN dispersion was instantly

ultrasonicated by probe sonicator (PCI analytics, Mumbai, India). Ultra sonication was done by adjusting frequency 0.5 for 30 min at 45% amplitude. A stable SLN suspension of voriconazole by micro emulsion (VMSLN) technique was obtained [20].

- A microemulsion is a thermodynamically stable, isotropic, transparent or translucent dispersion of two immiscible liquids (oil and water), stabilized by surfactants (a co-surfactant).
- In the nanoparticle method, the solid precursor (drug, polymer or inorganic salt) is first dissolved in oil phase (oil or water)
- Nanoparticles form when the microemulsion is broken (e.g., by precipitation, solvent evaporation or reaction) and the confined nanodroplets act as nanoreactors controlling particle size.

**Table 2: Tyes of Microemulsion Method For Solid-Liquid Nanoparticles**

Method	Description	Example
<b>W/O Microemulsion</b>	Solid precursor dissolved in aqueous phase , dispersed in oil with surfactant. Precipitation in droplet forms nanoparticles	Metal oxide nanoparticles
<b>Bath sonication</b>	ultrasonic bath where the container is placed in a water bath	Lower energy, mainly for dispersion and cleaning rather than major size reduction
<b>Tip/Probe Sonication with Pulsed Mode</b>	Alternating On-Off pulses	Prevents overheating maintains stability of nanoparticles
<b>Dual-frequency Sonication</b>	Combination of different frequencies	Improves dispersion and size uniformity

**2.3 Lyophilization**

To these above prepared aqueous dispersions, 2.5% w/v mannitol was dissolved as a cryoprotectant and then lyophilization was carried out for 24 hr. to verify physical stability and redispersibility. Firstly, prefreezing was done by freezing the mixture at -74°C, at 0.02mmHg pressure, and then vials were kept in adapter. The adapter was then fit into freeze-dryer (Lyophilizer FD-5-3, Allied Frost, New Delhi, India) and dispersion was lyophilized in a laboratory to get free flowing powder of voriconazole SLN

**2.4 Physicochemical Characterization of VCZ-SLN**

**2.4.1 Particle Size, Polydispersity Index, and Zeta Potential Measurements**

The particle size and polydispersity index (PDI) of the SLN were determined by photon correlation

spectroscopy (PCS) with a Zetasizer Nano ZS-90 (Malvern Instruments Ltd., Worcestershire, UK). Prior to analysis, samples of all SLN formulations were diluted with double-distilled water [21].The zeta potential measurements were done by laser-doppler-anemometer coupled with Zetasizer Nano ZS-90 (Malvern Instruments Ltd., Worcestershire, UK) to validate the electrophoretic mobility of particles. All the analysis were repeated in triplicate

**2.4.2 Determination of Entrapped VCZ**

It is the percentage of the actual mass of drug that was entrapped in the polymeric carrier, relative to the initial amount of loaded drug, and was calculated using the following equation

$$\text{Entrapment efficiency\%} = \frac{\text{Actual loading}}{\text{Theoretical loading}} \times 100$$

Theoretical drug loading was calculated from the amount of drug taken relative to the amount of total drug and excipients used in the preparation of nanoparticles as follows

$$\text{Total drug} = \frac{\text{Theoretical loading (\%)}}{\text{Total drug} + \text{Total excipients}}$$

For actual drug loading, the SLN dispersion prepared by dispersing 25mg of the lyophilized SLN powder in 5mL mixture of methanol: distilled water (1: 4) was centrifuged at 13000 rpm for 20 min. The clear supernatant was analyzed for free voriconazole content by measuring absorbance at 255 nm in an UV-visible spectrophotometer (Systronics, Mumbai). The total amount of drug present in the SLN was determined by dispersing 25mg of the lyophilized SLN powder in 10mL dichloromethane by sonication and filtering through a micro syringe filter (0.2 $\mu$ m) and analyzing the filtrate for voriconazole by measuring absorbance at 255nm using UV visible spectrophotometer. The following formula was used to calculate actual loading.

$$\text{Actual loading (\%)} = \frac{\text{Total drug} - \text{Free drug}}{\text{mg of lyophilized powder}} \times 100$$

#### 2.4.3 Fourier Transform Infrared Spectroscopy (FTIR) Analysis.

FTIR spectra of prepared SLN were recorded by Bruker spectrophotometer (Bruker IFS 66/S, Germany), using the potassium bromide (KBr) disk technique (5mg samples for 100mg dry KBr). KBr discs of the lyophilized formulations were prepared and analyzed at the wavelength range of 4000– 400 cm<sup>-1</sup>.

#### 2.4.4 Electron Microscope Examination.

The morphological observation of the VCZ loaded SLN was performed by transmission electron microscope (TEM). The samples of nanoparticles were stained with 2% (w/v) phosphotungstic acid. The nanoparticle suspension (5–10  $\mu$ L) was placed on the copper grids with films for viewing by TEM (Hitachi H- 7500, Tokyo, Japan) [22]. Digital micrograph and imaging viewer software was used to capture the image.

#### 2.4.5 Powder X-Ray Diffraction (PXRD) Analysis

PXRD was done to examine the crystalline state of the formulated SLN. The X-ray powder diffraction patterns of the samples were recorded with the XPERT-PRO multipurpose X-ray diffractometer (PAN analytical, Netherlands) using the PRS measurement program using Ni-filtered, CuK $\alpha$  radiation generated at 45 kV, and a current intensity of 40 mA. The diffraction angle range of the instrument was operated over a range of 2 $\theta$  angles from 5° to 40°.

#### 2.4.6 Differential Scanning Calorimetry (DSC) Analysis

Thermo grams of the different samples were obtained using a DSC TA-60 (Shimadzu, Tokyo, Japan) 208 calorimeter. Samples (3–5mg) were heated in crimped aluminum pans from 40°C to 200°C at a scanning rate of 10°C /min. Analyses were carried out under an inert nitrogen purge (35 mL/min) and an empty pan of alumina was used as reference in every case.

#### 2.5 In Vitro Drug Release from VCZ-SLN

The *in vitro* drug release studies were carried out in the modified USP dissolution apparatus 1 (37  $\pm$  0.5°C) containing a two-sided open glass cylinder for 12 hr. The diffusion barrier was dialysis membrane, and molecular weight cut-off 12000–14000 A (Himedia, Mumbai) was a release barrier. A presoaked dialysis membrane was adapted to the terminal portion of the glass cylinder. In each case, solid lipid nanosuspension (5 mL) was accurately introduced into the glass cylinder from the open side and this cylinder was fixed on the stirrer. The stirrer was suspended in 100mL dissolution of simulated tear fluid (pH 7.4) medium maintained at 37°C  $\pm$  0.5°C at 100rpm [23].

Aliquots of samples were withdrawn at predetermined time intervals with volume replacement. The withdrawn samples were analyzed for drug content, by measuring absorbance at 255 nm in the UV-visible spectrophotometer (Systronics, Mumbai, India). Sink conditions were maintained throughout the release period. Data obtained in triplicate were analyzed graphically; that is, percent drug release versus time graph was plotted.

#### 2.6 Release Kinetics

The kinetics of voriconazole release from solid lipid nanoparticles was determined using the release kinetics method of drug release into various kinetic equations: zero-order release kinetics, first-order release kinetics, and Higuchi model. The release data obtained was calculated using various parameters. The parameters “*n*” and time component “*k*,” the release rate constant, and “*R*” the regression coefficient was determined by Korsmeyer - Peppas equation to understand the release mechanism.

#### 2.7 Corneal Permeation Studies

Drug permeation studies were carried out by putting the voriconazole solid lipid nanoparticles (5 mL) on a freshly excised goat cornea [24]. The fresh, whole eyeballs of goats were obtained from a local butcher's shop and transported to the laboratory chilled in normal saline (4°C).

The cornea was then carefully excised along with 2 to 4mm of surrounding scleral tissue and was washed with normal saline until the washing was free from protein. The excised cornea was fixed between the clamped donor and receptor compartments of an all-glass modified Franz diffusion cell in such a way that its epithelial surface faced

the donor compartment at a temperature of  $37 \pm 0.5^\circ\text{C}$ . The corneal area available for diffusion was  $0.75 \text{ cm}^2$ . The receptor compartment was filled with 10mL freshly prepared simulated tear fluid (pH 7.4), and all air bubbles were expelled from the compartment. The whole corneal preparation procedure was completed within 1 hr. after the sacrifice of goat. The aliquots (1mL) of the formulated nanoparticles were placed on the excised cornea and the opening of the donor cell was sealed with a glass cover slip to prevent evaporation.

The acceptor solution was kept at  $37^\circ\text{C}$  with constant stirring using a Teflon-coated magnetic stir bead. The permeation study was carried out for 120min, and samples were withdrawn from the receptor at predetermined time intervals [25].The withdrawn samples were analyzed for drug content by measuring absorbance at 255 nm in a UV/Visible spectrophotometer (Systronics, Mumbai, India).

### 3. Result and Discussion

The SLNs of voriconazole were projected to prepare by two different techniques, in order to check the influence of these techniques on physicochemical characteristics. SLN prepared by ultrasonication method relies on the dispersing technique in which sufficient high-energy input was necessary to break down the droplets into the nanometer range. It is predominantly effective in breaking up aggregates and in reducing the size and decreasing the polydispersity of nanoparticles which offers advantages, that is, easy handling, no critical parameters, and fast production process. Another method for formulating SLN, that is, microemulsion technique in which there is addition of a microemulsion to water, leads to precipitation of the lipid phase forming finer particles] [26]. Low mechanical energy input, easy handling, and so forth are certain advantages of microemulsion method.

**Table 3: Physicochemical characterization of VCZ loaded solid lipid nanoparticles.**

S. No.	Batches	Particle size (nm± SD)	Zeta potential (mV ± SD)	*PDI (±SD)	Entrapment efficiency (% ± SD)
1	*VUSLN-1	234±1.52	-22.71±0.63	0.327±0.01	70.26±0.09
2	*VUSLN-2	247±2.08††	-27.10±0.55††	0.192 ±0.02††	72.08±0.02††
3	*VUSLN-3	265±1.50††	-25.23±0.56††	0.261±0.07†	76.64±0.04††
4	*VUSLN-4	274±4.04††	-24.73±0.61††	0.291 ±0.03†	84.25±0.11††
5	*VUSLN-5	288± 4.58††	-28.86±0.58††	0.232±0.05†	61.91±0.04††
6	*VUSLN-6	308±3.51	-26.46±0.30	0.248 ±0.04	59.13±0.07††
7	*VUSLN-7	319±2.64†	-27.96±0.41††	0.188±0.02†	63.23±0.12††
8	*VUSLN-8	325±4.16††	-24.83±0.65††	0.337±0.06†	65.13± 0.05††
9	*VUSLN-9	335±4.50††	-23.46±0.40††	0.219±0.02†	72.50±0.05††
10	*VUSLN-10	343±3.51††	-28.6±0.36††	0.263±0.02†	60.17±0.05††

VUSLN: voriconazole loaded solid lipid nanoparticle prepared with ultrasonication method.\*VMSL N: voriconazole loaded solid lipid nanoparticle prepared with microemulsion technique.\*PDI : polydispersity index. \*Values are mean ± SD (n =3).†Statistically significant difference at  $p < 0.05$ ; ††statistically significant difference at  $p < 0.01$ , from control (VUSLN-4 and VMSLN-9) as determined by one-way ANOVA followed by Dunnett’s test.

#### 3.1 Particle Size and Polydispersity Index Analysis

The results of particle size of freshly prepared lyophilized VCZ loaded formulations are depicted in Table 2 which are formulated with 2 different techniques. All SLN formulations showed a mean particle size below 400nm which is an optimum size for ophthalmic delivery as the human eye can tolerate particles smaller than  $10 \mu\text{m}$ . The particle size of formulations, that is, VUSLN-1 to VUSLN-5 ranges from  $234 \pm 3.52\text{nm}$  to  $288 \pm 4.58\text{nm}$  with ultrasonication method and VMSLN-6 to VMSLN-10 ranges from  $308 \pm 3.52\text{nm}$  to  $343 \pm 3.51\text{nm}$  with microemulsion technique respectively. The particle size increases with increase in polymer concentration were basically due to increased viscosity of dispersed phase resulting in larger nanodroplets formation. Similar findings were observed in earlier studies on Eudragit RL 100 based nanoparticulate system [27]. The particle size of SLNs

prepared with microemulsion technique (VMSLN-6 to VMSLN-10) was significantly  $p < 0.01$  higher as compared to mean particle size of formulations (VUSLN-1 to VUSLN-5) prepared with the ultrasonication method. This was explained by the fact that ultrasonication method generally leads to the breakdown of particles into smaller droplets during the preparation process.

#### 3.2 Poly dispersity Index

The polydispersity index (PDI) is a marker of particle size distribution. Its value in case of submicron particles ranges from 0.15 to 0.3 indicates size homogeneity, while PDI greater than 0.3 results in heterogeneity. The polydispersity index of all SLNs was significantly  $p < 0.05$  varying from  $0.188 \pm 0.013$  to  $0.337 \pm 0.015$  as depicted in Table 2 indicating narrow size distribution which reveals the higher stability of solid lipid nanoparticles. Similar findings were reported in earlier

studies on cyclosporine A incorporated cationic solid lipid nanoparticles for ocular drug delivery.

### 3.3 Zeta Potential Analysis

Zeta potential is an important surface characterization technique which helps in determining the potential stability and surface charge of nanoparticulate system. Usually, absolute large negative or positive zeta potential value required for colloidal dispersion stability as electrostatic repulsion between particles with same charges avoids aggregation. All formulations of exhibited negative zeta potential values because of the presence of stearic acid (0.3% w/v), which were significantly  $p < 0.01$ , vary from  $-22.71 \pm 0.63$  mV to  $-28.86 \pm 0.58$  mV as depicted in which is closer to  $-30$  mV ensuring physical stability. Similar results have been reported in earlier studies on lopinavir solid lipid nanoparticles prepared by microemulsion technique.




Figure 1 = Effect on zeta potential. Mean  $\pm$  SD ( $n = 3$ ).

### 3.4 Entrapment Efficiency (EE%)

The corresponding percent entrapment efficiency of SLN was found to be satisfactory high which is ranging from  $61.91 \pm 2.04\%$  to  $84.25 \pm 1.11\%$  (VUSLNs) prepared by ultrasonication method and  $59.13 \pm 1.97\%$  to  $72.50 \pm 2.05\%$  (VMSLNs) prepared by microemulsion technique, respectively, as depicted in Table 2[28]. The results suggested that as the polymer concentration increases, the drug entrapment efficiency increased significantly ( $p < 0.01$ ) due to its higher viscosity. But further increase in polymer concentration (VUSLN-5 and VMSLN-10 containing higher concentration of polymer as compared to others) showed a decrease in entrapment efficiency, which is basically due to a decrease in drug loading, as entrapment efficiency is the ratio of actual drug loading and theoretical drug loading. Higher entrapment efficiency of SLNs prepared with the ultrasonication method is due to a smaller particle size as compared to the microemulsion technique.

### 3.5 Transform Infrared Spectroscopy (FTIR) Analysis

FTIR is the backup analysis for the authentication of stability of crystalline shield of SLNs. Figure 8.1 shows

stacked IR spectra of pure drug, lipid, polymer, and physical mixtures and the prepared lyophilized VCZ loaded SLNs. The voriconazole FTIR spectrum showed OH stretching at  $3200.09\text{--}3046.04$   $\text{cm}^{-1}$ , C-N stretching at  $1510.28\text{--}1451.28$   $\text{cm}^{-1}$ , and C-F stretching at  $1587.44\text{--}1451.28$   $\text{cm}^{-1}$ , respectively. Stearic acid showed IR absorption band of C=O stretching at  $1.700$   $\text{cm}^{-1}$ . Spectrum of Carbopol 934 exhibited OH stretching at  $3000\text{--}2950$   $\text{cm}^{-1}$  and the prominent peak between  $1750\text{--}1700$   $\text{cm}^{-1}$  corresponds to carbonyl C=O stretching band. The spectrum of mannitol exhibited OH stretching at  $3400$   $\text{cm}^{-1}$ , OH in plane bending at  $1420$   $\text{cm}^{-1}$ , C-O stretching at  $1081$   $\text{cm}^{-1}$ , and OH out of plane bending for alcohol at  $701$   $\text{cm}^{-1}$ [29]. The physical mixture of voriconazole, Carbopol 934, and stearic acid showed no major shifting of any functional peaks between the spectra of drug, lipids, polymer, and its physical mixtures. Hence, it was indicated that there was no interaction between the drug, lipids, and polymer used. The IR spectra of lyophilized nanoparticles (VUSLN-4) showed the characteristic peaks of stearic acid at  $1702$   $\text{cm}^{-1}$ , Carbopol 934 at  $2935$   $\text{cm}^{-1}$ , and mannitol at  $3389$   $\text{cm}^{-1}$  and  $1086$   $\text{cm}^{-1}$  correspond to OH stretching and C-O stretching, respectively, prepared with ultrasonication method. The same results were observed in case of lyophilized nanoparticles of voriconazole prepared by microemulsion technique. The characteristics peaks of drug in both the methods of SLN were diminished when compared with pure drug peak at same wave number ( $3197.80$   $\text{cm}^{-1}$ ). This indicated that the drug is dispersed in lipid matrix in a microcrystalline form and also the prominent peak of polymer in both methods of SLN could not be located due to dilution effect of lipids. Similar findings were observed in earlier studies on gatifloxacin solid lipid nanoparticles for ocular drug delivery.




Figure 2: FTIR spectrum of (a) voriconazole, (b) stearic acid, (c) voriconazole, stearic acid, and Carbopol physical mixture, (d) Carbopol 934, (e) mannitol, (f) VUSLN-4, and (g) VMSLN-9.

### 3.6 Differential Scanning Colorimetry (DSC) Analysis

DSC is the technique to investigate the melting and recrystallization behavior of the substance. The DSC thermograms of samples are represented in Figure 4. The thermogram of voriconazole is characterized by a sharp melting endotherm at 132.04°C and heat of fusion of 95.08 J/g. The thermal curve of stearic acid is characterized by a sharp melting endotherm at 56.18°C with heat of fusion of 157.19J/g. The physical mixture of voriconazole, stearic acid, and Carbopol 934 showed characteristic peak at 140.52C, 56.48C, and 83.32C, respectively with no

depression in the melting point. A broad endothermic peak was observed at 78C in the DSC scan of Carbopol 934[30]. The thermal behavior of mannitol is characterized by an endothermic peak at 165.96C with heat of fusion of 291.31 J/g. The DSC curve of lyophilized SLNs showed a small endotherm at 81.02C which corresponds to the melting point of Carbopol 934 followed by a sharp endotherm at 164.64C which appears to be the depressed endothermic peak of polymorph of mannitol. The thermograms did not show any melting peak of drug.

**Table 5: Kinetic profiles of *in vitro* drug release from solid lipid nanoparticles through dialysis membrane prepared by different techniques**

	Zero-order model		First-order model		Higuchi model		Korsmeyer-Peppas model			Hixson Crowell model	
VUSLN-1	0.8875	0.1075	0.9882	-0.0011	0.9925	3.0573	0.9957	0.4559	0.6995	0.9871	-0.0026
VUSLN-2	0.9276	0.1092	0.9891	-0.001	0.9917	3.2493	0.9944	0.5081	0.4820	0.9909	-0.0026
VUSLN-3	0.9526	0.1044	0.9852	-0.001	0.9919	3.3457	0.9949	0.5718	0.2854	0.9922	-0.0026
VUSLN-4	0.9773	0.1013	0.9323	-0.001	0.9793	3.4423	0.9923	0.6257	0.110	0.9678	-0.0027
VUSLN-5	0.9789	0.1004	0.9650	-0.0008	0.9720	3.1781	0.9885	0.6537	0.0072	0.9786	-0.0022
VMSLN-6	0.9632	0.1189	0.9245	-0.0013	0.9285	3.6661	0.9992	0.5843	0.2800	0.9640	-0.0032
VMSLN-7	0.9589	0.1145	0.8832	-0.0011	0.9581	3.5647	0.9824	0.6181	0.1620	0.9279	-0.0029
VMSLN-8	0.9601	0.1127	0.8738	-0.0011	0.9449	3.5609	0.9762	0.6635	0.020	0.9171	-0.0028
VMSLN-9	0.9653	0.1119	0.8609	-0.0010	0.9371	3.5845	0.9778	0.7037	0.1072	0.9078	-0.0028
VMSLN-10	0.9908	0.0945	0.960	-0.0007	0.9667	3.1574	0.9906	0.8909	0.7185	0.9744	-0.002

**Table 6: Degradation rate constant and shelf life of SLN formulations after 3-month storage.**

Batches	Degradation constant (K) in day <sup>-1</sup>	t90 (days)	Shelf life (years)
VUSLN-1	1.37×10 <sup>-4</sup>	763.25	2.09
VUSLN-2	1.59×10 <sup>-4</sup>	659.88	1.80
VUSLN-3	1.33×10 <sup>-4</sup>	783.99	2.14
VUSLN-4	1.08×10 <sup>-4</sup>	963.81	2.64
VUSLN-5	1.29×10 <sup>-4</sup>	811.54	2.22
VMSLN-6	1.32×10 <sup>-4</sup>	789.91	2.16
VMSLN-7	1.30×10 <sup>-4</sup>	803.77	2.20
VMSLN-8	1.42×10 <sup>-4</sup>	737.14	2.01
VMSLN-9	1.26×10 <sup>-4</sup>	826.98	2.26
VMSLN-10	1.63×10 <sup>-4</sup>	644.11	1.76

### 3.7 Stability Assessment.

All the SLN formulations were kept on storage for three months at 25C ± 2°C and 60% RH±5% resulted in increase in particle size (Figure 7(a)). Increase in particle size ranges from 234 ± 1.5nm to 301 ± 2.06nm with batches prepared with ultra ultra-sonication method and from 308.66 ± 3.5nm to 363.4 ± 1.25nm with micro micro-emulsion technique. Entrapment efficiencies of SLN formulations were lowered by 6%–10% prepared by both methods after 3-month storage at room temp as shown in Figure 7(b) [31]. All the formulations showed slight increase in zeta potential ranging from 3.2% to 4.4% during

room temperature storage conditions as depicted in Figure 7(c).

The degradation of voriconazole-loaded SLNs followed first-order kinetics. The degradation constant (K), t90 values, and shelf life of all the formulations at room temperature are shown in. The degradation rate constants (K) and shelf life (t90) at room temperature for all SLN formulations range from 1.08 × 10<sup>-4</sup> day<sup>-1</sup> to 1.62 × 10<sup>-4</sup> day<sup>-1</sup> and 644.11 to 963.8 days, respectively, as depicted in Table 4. The calculated t90 of optimized formulation (VUSLN-4) at room temperature was found to be 963.81 days confirming that the SLN would provide more than 2-year shelf life at room temperature.

## 4. Summary and Conclusion

The present investigation finally concluded that the lipophilic drugs like voriconazole can also be effectively incorporated in solid lipid (stearic acid) using tween 80 as stabilizer. The study was also able to explore the potential of both methods of preparation of voriconazole loaded solid lipid nanoparticles, that is, ultra sonication method and micro emulsion technique. During the preparation of SLN, Carbopol 934 was used as a controlled release agent. Increasing the concentration of the polymer (Carbopol 934) results in more sustained drug release of SLN due to formation of strong matrices due to its highly

cross-linked structure. In determination of particle size study, the SLNs were obtained below 400 nm for all formulations with good PDI and negative zeta potential with optimum physiochemical characteristics. The negative zeta potential and fine particle size help to prolong precorneal residence time. The PXRD and DSC indicated decrease of drug crystallinity in the nanoparticles. *In vitro* release and *ex vivo* corneal permeation of drug from SLNs were found promising without causing any significant effect on the corneal hydration level. The nanoparticle was found to provide biphasic release pattern initial burst release followed by sustained release which fitted best into Higuchi-square root release kinetics. The results demonstrated that SLN (VUSLN-4) prepared by ultra sonication method was able to sustain the drug release for up to 12 hours as compared to micro emulsion technique. The optimized formulation (VUSLN-4) would provide more than 2-year shelf life at room temperature. However, the resulting solid lipid nanoparticles seem to be promising for providing a solution to the challenge caused by unsuccessful ocular delivery.

## References

- [1]. R Malviya, A. Kumar, and P. K. Sharma, "Recent trends in ocular drug delivery: a short review," *European Journal of Applied Science*, vol. 3, no. 3, pp. 86–92, 2011.
- [2]. P. Tangri and S. Khurana, "Basics of ocular drug delivery systems," *International Journal of Pharmaceutical Biomedical Research*, vol. 2, no. 4, pp. 1541–1552, 2011.
- [3]. D. Achouri, K. Alhanout, P. Piccerelle, and V. Andrieu, "Recent advances in ocular drug delivery," *Drug Development and Industrial Pharmacy*, vol. 39, no. 11, pp. 1599–1617, 2013.
- [4]. D. M. Maurice and S. Mishima, "Ocular pharmacokinetics," in *Handbook of Experimental Pharmacology*, M. L. Sears, Ed., Springer, Berlin, Germany, 1984.
- [5]. S. Ding, "Recent developments in ophthalmic drug delivery," *Pharmaceutical Science and Technology Today*, vol. 1, no. 8, pp. 328–335, 1998.
- [6]. M. Kumar and G. T. Kulkarni, "Recent advances in ophthalmic drug delivery system," *International Journal of Pharmacy and Pharmaceutics Sciences*, vol. 4, no. 1, pp. 387–394, 2012.
- [7]. H. A. Patel, J. K. Patel, N. K. Patel, and R. R. Patel, "Ophthalmic drug delivery system-a review," *Der Pharmacia Lettre*, vol. 2, no. 4, pp. 100–115, 2010.
- [8]. M. Mudgil and P. K. Pawar, "Preparation and in Vitro/Ex Vivo evaluation of moxifloxacin-loaded PLGA nanosuspensions for ophthalmic application," *Scientia Pharmaceutica*, vol. 81, no. 2, pp. 591–606, 2013.
- [9]. M. A. Kalam, Y. Sultana, A. Ali, M. Aqil, A. K. Mishra, and K. Chuttani, "Preparation, characterisation, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system," *Journal of Drug Targeting*, vol. 18, no. 3, pp. 191–204, 2010.
- [10]. R. M. Khalil, A. Abd-Elbary, M. A. Kassem, M. M. Ghorab, and M. Basha, "Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam," *Pharmaceutical Development and Technology*, vol. 19, no. 3, pp. 304–314, 2014.
- [11]. N. V. Prajna, J. Mascarenhas, T. Krishnan et al., "Comparison of natamycin and voriconazole for the treatment of fungal keratitis," *Archives of Ophthalmology*, vol. 128, no. 6, pp. 672–678, 2010.
- [12]. L. B. Johnson and C. A. Kauffman, "Voriconazole: a new triazole antifungal agent," *Clinical Infectious Diseases*, vol. 36, no. 5, pp. 630–637, 2003.
- [13]. K. Ruckmani, M. Sivakumar, and P. A. Ganeshkumar, "Methotrexate loaded Solid Lipid Nanoparticles (SLN) for effective treatment of carcinoma," *Journal of Nanoscience and Nanotechnology*, vol. 6, no. 9-10, pp. 2991–2995, 2006.
- [14]. J. Youshia, A.O. Kamel, A. E. Shamy, and S. Mansour, "Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide," *International Journal of Nanomedicine*, vol. 2012, article 7, pp. 2483–2496, 2012.
- [15]. C. Wu, H. Qi, W. Chen et al., "Preparation and evaluation of a Carbopol/HPMC-based *in situ* gelling ophthalmic system for puerarin," *Yakugaku Zasshi*, vol. 127, no. 1, pp. 183–191, 2007.
- [16]. A. Sharma, M. Jindal, G. Aggarwal, and S. Jain, "Development of a novel method for fabrication of solid lipid nanoparticles: using high shear homogenization and ultrasonication," *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, vol. 1, no. 2, pp. 265–274, 2010.
- [17]. S. Sood, N. Jawahar, K. Jain, K. Gowtham Rajan, and S. N. Meyyanathan, "Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability," *Current Nanoscience*, vol. 9, no. 1, pp. 26–34, 2013.
- [18]. R. Katara and D. K. Majumdar, "Eudragit RL 100-based nanoparticulate system of aceclofenac for ocular delivery," *Colloids and Surfaces B: Bio interfaces*, vol. 103, pp. 455–462, 2013.

- [19]. U. Ghanshyam, P. Patel, and J. Patel, "Formulation and characterization of solid lipid nanoparticles dry powder inhaler containing triamcinolone acetonide," *International Journal of Research in Pharmacy and Chemistry*, vol. 1, no. 3, pp. 662–673, 2011.
- [20]. S. Das, P. K. Suresh, and R. Deshmukh, "Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery," *Nanomedicine: Nanotechnology, Biology, and Medicine*, Vol. 6, no. 2, pp. 318–323, 2010.
- [21]. M. Yadav and M. Ahuja, "Preparation and evaluation of nanoparticles of gum cordia, an anionic polysaccharide for ophthalmic delivery," *Carbohydrate Polymers*, vol. 81, no. 4, pp. 871–877, 2010.
- [22]. S.K. Motwani, S. Chopra, S. Talegaonkar, K. Kohli, F. J. Ahmad, and R. K. Khar, "Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation," *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 68, no. 3, pp. 513–525, 2008.
- [23]. A. Garud, D. Singh, and N. Garud, "Solid Lipid Nanoparticles(SLN): method, characterization and applications," *International Current Pharmaceutical Journal*, vol. 1, no. 11, pp. 384–393, 2012.
- [24]. P. Pawar, H. Kashyap, S. Malhotra, and R. Sindhu, "Hp- $\beta$ -CD voriconazole *in situ* gelling system for ocular drug delivery: *in vitro*, stability, and antifungal activities assessment," *BioMed Research International*, vol. 2013, Article ID 341218, 9 pages, 2013.
- [25]. R. H. Muller, K. M<sup>a</sup>der, and S. Gohla, "Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art," *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 50, no. 1, pp. 161–177, 2000.
- [26]. M. Cegnar, J. Kos, and J. Kristl, "Cystatin incorporated in poly(lactide-co-glycolide) nanoparticles: development and fundamental studies on preservation of its activity," *European Journal of Pharmaceutical Sciences*, vol. 22, no. 5, pp. 357–364, 2004.
- [27]. E. Basaran, M. Demirel, and B. Sirmagul, "Cyclosporine-incorporated cationic solid lipid nanoparticles for ocular delivery," *Journal of Microencapsulation*, vol. 27, no. 1, pp. 37–47, 2010.
- [28]. K. Manjunath, J. S. Ready, and V. Venkateswarlu, "Solid lipid nanoparticles as drug delivery systems," *Methods and Findings in Experimental and Clinical Pharmacology*, vol. 27, no. 2, pp. 127–144, 2005.
- [29]. J. S. Negi, P. Chattopadhyay, A. K. Sharma, and V. Ram, "Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self-nano-emulsification (SNE) technique," *European Journal of Pharmaceutical Sciences*, vol. 48, no. 1-2, pp. 231–239, 2013.
- [30]. M. Malhotra and D. K. Majumdar, "*In vivo* ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note," *AAPS Pharm SciTech*, vol. 6, no. 3, pp. E523–E526, 2005.
- [31]. F.-Q. Hu, S.-P. Jiang, Y.-Z. Du, H. Yuan, Y.-Q. Ye, and S. Zeng, "Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system," *Colloids and Surfaces B: Bio interfaces*, vol. 45, no. 3-4, pp. 167–173, 2005.